The Plateau State Drugs and Medical Commodities Management Agency (PS-DMCMA) has begun local production of pharmaceutical products to enhance drug accessibility and affordability within the state.
The agency’s Executive Secretary, Kim Bot, made the announcement during an interview on Thursday in Jos.
Bot, a pharmacist, revealed that the agency has successfully produced five pharmaceutical products, marking a significant step toward self-reliance in healthcare.
Locally Manufactured Products:
The locally produced pharmaceuticals include:
Cough syrup
Antacid (Mist. Magnesium Trisilicate) for oral use
Methylated spirit An antiseptic for external Use
Surface sanitizers
Bot stated that these products have undergone efficacy testing with outstanding results, confirming their quality and effectiveness.
In addition to production, Bot highlighted the agency’s state-of-the-art pharmaceutical-grade warehouse, which underscores the Plateau State government’s commitment to ensuring a safe, efficient pharmaceutical supply chain.
The warehouse features advanced temperature control, inventory management systems, and robust security.
“This warehouse is a crucial link between pharmaceutical manufacturers and healthcare providers, benefiting countless patients who depend on these essential medicines,” Bot explained.
NAFDAC Registration and Certification:The agency plans to scale up production after securing registration and certification from the National Agency for Food and Drug Administration and Control (NAFDAC).
Bot also noted that most raw materials are locally sourced, with only one ingredient being imported.
He emphasized that this local manufacturing initiative will improve access to and the affordability of essential medicines in the state, stating, “These efforts will significantly enhance accessibility and affordability.”
Bot commended Governor Caleb Mutfwang for his dedication to improving healthcare services in Plateau State, acknowledging the governor’s role in ensuring residents receive top-quality care.
Context:
Nigeria’s pharmaceutical sector is making strides in increasing local drug production, aiming to reach 70% manufacturing capacity.
According to NAFDAC’s Director-General, Prof. Mojisola Adeyeye, local production has already exceeded 30% and is nearing 40%.
The goal is to further reduce reliance on imported medicines, with NAFDAC approving 105 out of 143 applications for drug manufacturing facilities, all adhering to WHO and NAFDAC’s Good Manufacturing Practice (GMP) standards.
These initiatives aim to enhance drug security, affordability, and self-sufficiency in Nigeria’s pharmaceutical sector.